Education
About Us
Working with TipRanks
Follow Us
BioMark Diagnostics (TSE:BUX)
:BUX
BUX Stock Chart & Stats
C$0.46
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.46
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.20 - C$0.55
Previous CloseN/A
Volume0.00
Average Volume (3M)16.46K
Market Cap
C$56.75M
Enterprise ValueC$56.18M
Total Cash (Recent Filing)C$1.55M
Total Debt (Recent Filing)C$153.22K
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Mar 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding105,090,210
10 Day Avg. Volume19,330
30 Day Avg. Volume16,464
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)-41.95
Price to Sales (P/S)156.67
P/FCF Ratio-25.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA low debt-to-equity (~0.18) gives the company financial flexibility and lowers interest burden, which is durable for a development-stage diagnostics firm. This reduces near-term default risk and preserves capacity to raise equity or allocate cash to R&D and clinical validation without heavy servicing costs.
Positive Gross Margin BaseA roughly 29.9% gross margin indicates the company’s test economics can cover direct costs. With scale and productivity improvements, this margin provides a structural foundation to absorb fixed R&D and commercialization costs, supporting pathway to improved operating leverage as revenues recover or grow.
Focused Diagnostics FranchiseConcentration on blood-based diagnostics for early disease detection targets a structural, growing market (screening/monitoring). This specialization supports durable competitive positioning, clearer clinical development pathways, and potential recurring revenue from monitoring or licensing if assays gain clinical adoption.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow (~-$1.4M TTM) means the business cannot self-fund development and commercialization. That creates durable dependence on external financing, raising dilution and execution risk for multi-stage clinical validation and market expansion unless cash generation materially improves.
Declining RevenuesA 20% TTM revenue decline signals weakening top-line traction for a small revenue base, undermining operating leverage and the ability to scale fixed-cost investments. Without stabilizing or growing revenues, investments in validation and commercialization become harder to justify and slow path to breakeven.
Deep Negative ProfitabilityExtremely negative net margins (~-1,340%) and negative returns on equity reflect structural unprofitability. This persistent loss profile raises long-term dilution risk, limits reinvestment capacity, and pressures management to secure financing instead of executing strategic growth, unless clinical wins change economics.
BioMark Diagnostics News
BUX FAQ
What was BioMark Diagnostics’s price range in the past 12 months?
BioMark Diagnostics lowest stock price was C$0.20 and its highest was C$0.55 in the past 12 months.
What is BioMark Diagnostics’s market cap?
BioMark Diagnostics’s market cap is C$56.75M.
When is BioMark Diagnostics’s upcoming earnings report date?
BioMark Diagnostics’s upcoming earnings report date is Mar 03, 2026 which is in 12 days.
How were BioMark Diagnostics’s earnings last quarter?
BioMark Diagnostics released its earnings results on Nov 29, 2025. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.
Is BioMark Diagnostics overvalued?
According to Wall Street analysts BioMark Diagnostics’s price is currently Overvalued.
Does BioMark Diagnostics pay dividends?
BioMark Diagnostics does not currently pay dividends.
What is BioMark Diagnostics’s EPS estimate?
BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioMark Diagnostics have?
BioMark Diagnostics has 105,090,210 shares outstanding.
What happened to BioMark Diagnostics’s price movement after its last earnings report?
BioMark Diagnostics reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.448%.
Which hedge fund is a major shareholder of BioMark Diagnostics?
Currently, no hedge funds are holding shares in TSE:BUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioMark Diagnostics
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Technical Analysis
Spectral Medical
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
ZYUS Life Sciences
―
Sona Nanotech Inc
―
Options Prices
Currently, No data available
---